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Objective: It has been suggested that specific psychotic symptom clusters may be
explained by patterns of biological abnormalities. The presence of first rank symptoms
(FRS) has been associated with cognitive abnormalities, e.g., deficits in self-monitoring or
in the experience of agency, suggesting that a specific network of neural abnormalities
might underlie FRS. Here, we investigate differences in cortical and subcortical brain
volume between patients with and without FRS.
Methods: Three independent patient samples (referred to as A, B, and C) with different
mean ages and in different illness stages were included, leading to a total of 348 patients
within the schizophrenia-spectrum. All underwent magnetic resonance imaging of the
brain. In addition, the presence of FRS was established using a diagnostic interview.
Patients with (FRS+, A: n=63, B: n=129, and C: n=96) and without FRS (FRS , A:
n=35, B: n=17, and C: n=8) were compared on global and local cortical volumes as
well as subcortical volumes, using a whole brain (cerebrum) approach.
Results: Nucleus accumbens volume was significantly smaller in FRS+ as compared
with FRS  in sample A (p<0.005). Furthermore, FRS+ showed a smaller volume of
the pars-opercularis relative to FRS  in sample B (p<0.001). No further significant
differences were found in cortical and subcortical volumes between FRS+ and FRS 
in either one of the three samples after correction for multiple comparison.
Conclusion: Brain volume differences between patients with and without FRS are,
when present, subtle, and not consistent between three independent samples. Brain
abnormalities related to FRS may be too subtle to become visible through structural brain
imaging.
Keywords: schizophrenia, first rank symptoms, structural MRI image analysis, subcortical volume, corticalvolumes
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Introduction
Early in the twentieth century, Kurt Schneider introduced the
concept of first rank symptoms (FRS). He identified certain
symptoms as being characteristic of schizophrenia and therefore
exhibiting a “first-rank” status in the hierarchy of potentially diag-
nostic symptoms. These symptoms are auditory hallucinations,
passivity experiences (delusions of control), thought withdrawal,
thought insertion, thought broadcasting, and delusional percep-
tion. FRS are indeed not uncommon in patientswith a diagnosis in
the psychosis spectrum, but incidence estimates are highly incon-
sistent. Studies show that between 55 and 84%of patients suffering
from psychosis (or schizophrenia, depending on the inclusion
criteria) experience at least one first rank symptom during the
course of illness (1–4). Consequently, over the last decades the
concept has lost its diagnostic applicability (5). One of the reasons
is accumulating evidence showing that FRS are not only distinctive
for schizophrenia but are also present in patients with bipolar
disorder or other non-schizophrenic psychoses (3, 5–7). However,
for research purposes, a well-defined cluster of symptoms may
help unravel the underlying mechanisms of psychosis. Indeed,
studying symptom clusters within the psychosis spectrum might
lead to more homogeneous groups of individuals who share a
unique biological signature (8).
A model that explains the presence of FRS in terms of a
specific pattern of biological or cognitive abnormalities is the
motor-prediction model (9). This neurocognitive model suggests
that schizophrenia patients are unable to distinguish between
actions that are brought about by external forces and those that
are generated internally. Prediction of action consequences is
crucial in order to self-monitor actions and ascribe agency over
actions to self or others. The model argues that an internal
copy of a movement-producing signal as generated by the
motor system, a so-called efference copy, is compared with the
actual sensory signals that result from the action. Agency over
own actions arises when the efference copy and the sensory
feedback matches. Evidence suggests that psychotic patients
with FRS show abnormalities in such predictions, consequently
leading to mismatches between the actual sensation with the
predicted sensation leading to the interpretation of externally
generated movements or thought (10). Indeed, cognitive studies
on agency provide evidence for deficits in the prediction of
sensory consequences of one’s actions, consequently leading to
a disturbed sense of agency (10–12). A disconnection between
frontal and parietal areas has been suggested to underlie deficits
in motor prediction. In healthy individuals, the frontal cortex is
assumed to initiate actions while parietal regions represent the
current and predicted state of limbs (9).
Studies using Magnetic Resonance Image (MRI) scans of
schizophrenia patients have shown associations between FRS and
reduced brain volume in the inferior partial lobule (13–15), how-
ever, not exclusively. The presence of FRS has also been inversely
associated with gray matter volumes of the para-hippocampal
gyrus, frontal cortex, cingulate gyrus, basal ganglia, and thalamus
(16, 17). In contrast, earlier MRI studies found no associations
between FRS and brain volume (18), leaving doubt whether FRS
are related to abnormal structural brain measures. In the current
study, we aimed to investigate differences in cortical and sub-
cortical volumes between patients with and without first rank
symptoms. We choose to take a whole brain (cerebrum) approach
and not to focus on predetermined regions of interest (ROIs), due
to the discrepancy in ROIs found so far. We included three inde-
pendent samples with patients in different stages of the disease in
order to replicate potential findings across these samples.
Materials and Methods
Clinical Assessment
Three independent samples were included consisting of patients
with affective and non-affective psychosis. In all samples, diag-
nosis and presence and severity of symptoms were based on the
Comprehensive Assessment of Symptoms and History interview
[CASH; (19)]. This diagnostic tool is developed to provide infor-
mation about the current and past symptoms of psychosis in the
affective and schizophrenia spectrum. The CASH was adminis-
tered by experienced clinicians. In Sections 6 and 7 of the CASH,
symptom type and severity of positive psychotic symptoms were
assessed on both a life-time (dichotomous) and a present state
scale (six-point Likert scale from0= absent to 5= severe). Section
6 describes delusions, i.e., paranoid, jealousy, guilt, grandiosity,
religious, somatic, reference, alien body control, and abnormal
perception phenomena, such as thought reading, thought broad-
casting, thought insertions, and thought withdrawal. The latter
five symptoms are defined as part of first rank delusions (FRD).
Section 7 describes auditory hallucinations (including audible
thoughts), voices commenting and conversational voices, somatic,
tactile, olfactory, and visual hallucinations. The first three are
considered first rank hallucinations (FRH). The presence of either
FRD or FRH represented the presence of FRS (19).
In addition, the Positive andNegative Syndrome Scale (PANSS)
was administered in all three samples. The PANSS is a 30-item
rating scale with three subscales representing positive, negative,
and general psychopathology symptoms. Each symptom is rated
on a seven-point scale (1= absent to 7= extremely severe) (20).
In sample A, only the PANSS remission criteria were adminis-
tered, i.e., remission is achieved when eight symptoms do not
exceed a score of mild (severity criterion). These eight core symp-
toms together represent the psychotic, disorganized, and negative
symptom dimensions of schizophrenia (21).
Subjects
In this study, we included three independent patient samples.
Sample A was recruited in Amsterdam, samples B and C were
recruited in Utrecht. The ethics committee of Academic Medical
Center in Amsterdam (AMC) and UMC Utrecht approved this
study.
Sample A
A total of 98 patients with a psychotic disorder (schizophrenia:
n= 68, schizophreniform disorder: n= 10, schizoaffective disor-
der: n= 15, substance induced psychotic disorder: n= 2, psy-
chosis not other specified: n= 3) were clinically obtained from the
Early Psychosis Department of the AMC between June 2004 and
December 2011. This department is specialized in treating young
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TABLE 1 | Demographic and clinical differences between three samples.
Sample A (N= 98) Sample B (N= 146) Sample C (N= 104) Test statistics p Direction
Mean age, years (SD) 22.5 (3.1) 26.4 (5.8) 36.0 (11.1) F (2,347)= 94.4 <0.001 A<B<C
Female/male (% male) 13/85 (87%) 28/118 (81%) 33/73 (69%) χ2 (2)= 10.3 0.006 A and B<C
Mean GAF (SD) 35.1 (9.9) 51.7 (15.5) 52.3 (17.6) F (2,305)= 44.4 <0.001 A<B and C
Mean illness duration (years) (SD) 2.1 (2.2) 3.8 (3.4) 14.7 (10.6) F (2,342)= 124.3 <0.001 A and B<C
Mean number psychotic episodes (SD) 1.1 (0.3) 1.7 (1.1) 12.3 (30.1) F (2,298)= 16.0 <0.001 A and B<C
Medication typical/atypical/both 10/81/3 9/101/3 10/35/40 χ2(4)= 93.2 <0.001 A and B<C
Drug abuse/dependence/both/none 25/25/4/44 18/32/13/83 – χ2(3)= 9.49 0.023 A>B
adults with recent-onset psychotic disorders. Patients had a mean
age of 22.5 years, themajority wasmale (87%) and illness duration
at time of scanning was on average 2.1 years (defined as time since
first onset of psychotic symptoms). For further demographic and
clinical information, see Table 1.
Sample B
A total of 146 patients with a non-affective psychotic disorder
(schizophrenia: n= 118, schizophreniform: n= 8, schizoaffective
disorder: n= 19 and delusional disorder: n= 1) were selected
from the baseline measurement of the Genetic Risk and OUtcome
of Psychosis (GROUP) study. This naturalisticmulti-center follow-
up study with three assessments within a 6-year time-span started
in 2004 (22). Patients recruited at the University Medical Centre
Utrecht (UMCU) were included. Patients had a mean age of 26.4,
the majority was male (81%), and illness duration at time of
scanningwas on average 3.8 years (defined as time since first onset
of psychotic symptoms). For further demographic and clinical
information, see Table 1.
Sample C
Sample C includes 104 patients with a schizophrenia spectrum
disorder who took part in a 5-year longitudinal brain imaging
study at the UMCUbetween 1995 and 2004 (23, 24). Patients were
recruited from various in- and out-patient clinics and met the
DSM-IV criteria for schizophrenia or schizophreniform disorder.
Those with schizophreniform disorder met the criteria for the
diagnosis of schizophrenia after 1 year of illness. Substance depen-
dence or abuse 6months prior to inclusion led to exclusion of the
study. For the current study, baseline informationwas used, except
when the clinical information was insufficient. In that case, when
possible, information from follow-up was used. Patients were of
a mean age of 36.4 years, the majority was male (70%) and illness
duration at time of scanning was on average 14.7 years (defined as
time since first onset of psychotic symptoms). For demographic
and clinical variables of the current sample, see Table 1.
Patients were not included when information from the CASH
or clinical records was insufficient to obtain information on the
lifetime presence of FRS, scans were of poor quality, or processing
of the MRI scan was unsuccessful, leading to the exclusion of
15, 21, and 19 scans from sample A, B, and C respectively. All
numbers presented in tables and figures are those after exclusion
of these subjects.
Each samplewas divided in two groups based on the presence of
FRS. The FRS+ group consisted of patients who had experienced
at least one FRD or FRH life-time or present-state according to
the CASH. When this was not the case, patients were part of the
FRS  group.
Imaging
Magnetic resonance images of the brain were acquired. Sample
A was scanned on a Philips Intera 3T. A 3-dimenisonal T1-
weighted image was acquired with an 8-channel SENSE head coil.
Images were acquired in a clinical setting. Consequently, TEs and
TRs range between 4.585–4.604ms and 9.735–9.833ms, respec-
tively. Furthermore, flip angle= 8°, FOV= 256 256 and slice
thickness= 1.2mm. Sample B was scanned on a Philips Achieva
1.5T, SENSE 6 channel, TE= 4.6ms, TR= 30ms, flip angle= 30°,
FOV= 256 256 and slice thickness= 1.2mm. Sample C was
acquired on a Philips Intera 1.5T, with TE= 4.6ms, TR= 30ms,
flip angle= 30°, FOV= 256 256, and slice thickness= 1.2mm.
Post processing of sample A was done on the e-Bioinfra Gate-
way (25), a web application that provides facilitated access to
the Dutch Grid infrastructure to analyze large data collections.
Samples B and C were processed on the neuroimaging computer
network at the Department of Psychiatry, UMCU, Utrecht. All
images were coded to ensure investigator blindness to subject
identification and diagnosis.
Cortical and subcortical reconstruction and volumetric seg-
mentation was performed with the Freesurfer image analysis
suite v5.1.0, which is documented and freely available for down-
load online1. Processing of a volumetric T1-weighted image
includes automated Talairach transformation, intensity normal-
ization (26), removal of non-brain tissue (27), segmentation of
the subcortical white matter and deep gray matter volumetric
structures, including accumbens, amygdala, caudate, hippocam-
pus, pallidum, putamen, and thalamus (28, 29), tessellation of
the gray matter white matter boundary, and automated topology
correction (30–33). Next, the surface is inflated (32) for registra-
tion to a spherical atlas, which utilizes individual cortical folding
patterns to match cortical geometry across subjects (32). This is
used to parcellate the cerebral cortex into a map with units based
on gyral and sulcal structure (34). A total of 68 cortical ROIs
(left and right ROI were summed to represent total volume) and
7 subcortical ROIs (thalamus, hippocampus, amygdala, caudate,
accumbens, pallidum, and putamen) were included in this study.
The maps produced are not restricted to the voxel resolution
of the original data, thus are capable of detecting submillimeter
differences.
1http://surfer.nmr.mgh.harvard.edu
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All segmentations were visually checked using the guidelines
and scripts of the ENIGMA project2 (35). Pial surface segmenta-
tionswere visually checked and, when needed,manually corrected
for mislabeling of tissues prior to analysis. Specific attention was
put on the inspection of delineation of the cortical gray and white
matter tissues. Parts mislabeled as gray matter (e.g., remaining
skull/dura mater) were removed. Further, mapping of the ROIs
and subcortical structures was assessed by visually checking inter-
nal slice and external 3D labeling. Finally, an outlier analysis for
each ROI was done to indicate further visual checking for possible
mislabeling. An ROI is labeled as an outlier when the ROI value
is higher or lower than the group average ROI by multiplying
the standard deviation with 2.698, leading to a 0.99 confidence
interval. This was donewith project R version 3.0.1, a free software
environment for statistical computing and graphics available for
download online3.
Statistical Analysis
All analyses were performed using the Statistical Package for
Social Sciences (SPSS) version 20.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Demographics
First, we compared the three samples on age, gender, GAF score,
illness duration, number of psychotic episodes with one-way anal-
yses of variance (ANOVA), and χ2 tests. Second, similar analyses
were performed within each sample to compare patients with and
without FRS.
Group Comparison on Brain Measures
FreeSurfer processing of the brain images generated volumes of
cortical and subcortical ROIs for each individual subjects. Within
each sample, patients with and without FRS were compared on
each ROI using univariate GLM. ROI volume was included as
dependent variable and group (FRS+/FRS ) entered the analysis
as independent variable. Age and gender were added as covari-
ates. When significant ROI differences between patients with and
without FRS are found, it was investigated if the effect in local
cortical volumewas explained by cortical thickness or surface area
of this ROI. Since there is an uneven distribution of the number
of patients per FRS group within the samples, Levene’s test was
used to check for homogeneity of variances. To correct formultiple
comparisons False Discovery Rate (FDR) was controlled at 0.05
(36). In addition, we report findings with an uncorrected p< 0.01.
Results
Demographics
As expected, the three samples differed significantly on age, ill-
ness duration, and number of psychotic episodes (all significantly
higher in sample C, except for age where all groups differed sig-
nificantly from one another). In addition, significant differences
were found for gender ratio (significantly more females in sample
C), GAF score (significantly lower in sample A), and current
2http://enigma.ini.usc.edu/
3http://www.r-project.org/
antipsychotic medication use (significantly more patients on typ-
ical antipsychotics in sample C). In addition, intracranial volume
(ICV) did not differ significantly between FRS+ and FRS .
Table 2 shows the comparison of demographic and clinical
variables between patients with and without FRS within each
sample. No significant differences were found between FRS+ and
FRS  on any of the demographic and clinical variables.
Group Comparison on Brain Measures
Levene’s homogeneity tests were not significant, suggesting equal
variances in all ROIs between the FRS groups in all three samples.
In sample A, a smaller nucleus accumbens was found in FRS+ rel-
ative to FRS . In sample B, a smaller volume of pars-opercularis
cortex was found in FRS+ patients as compared to FRS . See
Figure 1. No further significant differences were found in cortical
and subcortical volumes between FRS+ and FRS  after FDR
correction.Table 3 shows the results that reached the uncorrected
p< 0.01. Post hoc analysis of the pars-opercularis in sample B
showed that cortical surface area in FRS+ (3.08 cm2) was smaller
than in FRS  (3.38 cm2; F(1,139)= 9.38 p= 0.003). Findings did
not changewhen adding ICVor illness duration as covariate. Also,
excluding patients with substance induced psychotic disorder,
delusional disorder, and schizoaffective disorder did not change
our findings.
Discussion
The aim of this study was to determine whether patients with
first rank symptoms (FRS) differ in cortical and subcortical vol-
umes from patients without these symptoms. The main finding
is the lack of volume differences in the previously reported areas
between these groups. This is consistent with previous research
demonstrating in a study of 71 patients with schizophrenia that
the severity of FRS showed no association with brain volume (18).
The only findings that reached statistical significance were
a smaller nucleus accumbens and pars-opercularis cortex in
patients with FRS as compared with those without FRS, in sample
A and B respectively. That significant group differences were not
replicated between the three sample may indicate that these results
are random, although the areas we found do have relevance for psy-
chosis in general, and FRS in particular. The nucleus accumbens, as
part of themesolimbic dopamine circuit, has been associated with
reward, attention, and salience (37, 38), all abnormal in patients
with psychotic symptoms. Abnormal dopaminergic signaling is
associated with misattributing salience to stimuli and prediction
errors, leading to positive symptoms, e.g., delusional beliefs such
as FRD (38, 39). In addition, the pars-opercularis is part of Broca
area, which plays a major role in semantic processes. Abnormali-
ties in this area have been associated with the presence of auditory
hallucinations (40), which are part of FRS. Here, we showed that
the smaller pars-opercularis volume in patients with FRS could
be explained by a smaller surface. Usually, abnormal surface is
assumed to have a neurodevelopmental origin. As far as we know,
there is no evidence that abnormalities in neurodevelopment
lead to the emergence of specifically FRS. However, it remains
unclear why volume decreases in the nucleus accumbens or pars-
opercularis are only present in one of the included samples. The
samples included in this study did differ significantly on several
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– potentially relevant variables, such as illness duration, age, and
outcome.
In previous studies, we compared the patient samples that
are included in the current study to age- and gender-matched
controls samples. The reported brain volume abnormalities are
conform findings froma comprehensivemeta-analysis integrating
studies comparing brain volumes between (medication naive)
schizophrenia patients to controls (41). That is, in sample A
case-control differences showed smaller volumes of the amyg-
dala, putamen, insula, para-hippocampus, and fusiform gyrus in
patients with a non-affective psychotic disorder as compared with
controls (42); in sample B case-control differences showed smaller
volumes of the whole brain and cerebral white matter, increased
volumes of the third and lateral ventricles, as well as local areas
of cortical thinning, and reduced gray matter density in patients
with schizophrenia as compared with controls (43), and finally in
sample C patients demonstrated volume decreases in whole brain,
cerebral gray matter, prefrontal gray and whiter matter volumes
as well as volume increases in the lateral and third ventricles
and peripheral CSF in schizophrenia patients as compared with
controls (23, 44).
Previous studies suggested that smaller volumes of the (infe-
rior) partial lobule, para-hippocampal gyrus, frontal cortex, cin-
gulate gyrus, basal ganglia, and thalamus were associated with the
presence of severity of FRS (14, 17). In these studies, it cannot
be ruled out that the presence and severity of symptoms other
than FRS are responsible for the association. Indeed, correlations
between structural brain abnormalities and any one of the three
main symptom dimensions, i.e., negative, positive, and disorga-
nization, have been reported (45–48). For example, Maruff et al.
(15) showed that patients with FRS had more severe symptoms
of reality distortion as compared to patients without FRS. This
might implicate that the volume reduction in parietal and frontal
area is not completely due to the presence of FRS per se, but could
also be explained by disorganization symptoms. Such symptoms
have indeed an effect on total brain and cerebellar volume (46).
Additionally, the severity of positive symptoms (which FRS are
part of) have been found to correlate with reduced volumes in
frontal and temporal regions (45), implicating that it is unclear
what specific type of positive symptoms (e.g., FRS or paranoid
delusions)may be responsible for the volume reduction. However,
it is important to note that the reported correlation coefficients
between cortical measures and symptom severity are generally
low, suggesting that symptom severity explain only a small part
of the variation in brain volume. In our study, we investigated
whether patients with and without FRS differed on any of the
other symptom measures or on number of psychotic episodes.
This was not the case in either one of the three samples. This
suggests that the few volume differences between FRS+ and FRS
we found (e.g., smaller nucleus accumbens and pars-opercularis
in FRS patients) cannot be explained by these clinical differences
between the groups.
Nevertheless, our finding of a subtle relationship between struc-
tural brain abnormalities and FRS does not exclude a stronger asso-
ciation between abnormal brain functioning and FRS. Functional
imaging studies have found a relationship between increased
regional cerebral blood flow (rCBF) and severity of FRS (49, 50). In
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FIGURE 1 | On the X axis the FRS+ (dark-colored circles) and
FRS  (light-colored crosses) groups are displayed for each
sample (A, red; B, blue; and C, green). The Y axis represents the
total volume (cm3). *Indicates FDR correct significant differences.
(A) In sample A, volume of the nucleus accumbens is significantly
smaller in FRS+ as compared with FRS . (B) In sample B, volume of
the pars-opercularis cortex is significantly smaller in FRS+ as compared
with FRS .
TABLE 3 | Brain volume differences between patients with and without FRS in all three samples.
Sample A Sample B Sample C
FRS+
(n= 63)
FRS 
(n= 35)
F p FRS+
(n= 129)
FRS 
(n= 17)
F p FRS+
(n= 96)
FRS 
(n= 8)
F p
Cortical; pars-opercularis (mean
volumeSD cm3)
9.540.18 9.590.25 0.03 0.88 9.060.11 10.180.30 11.99 0.0007 8.740.15 9.000.540 0.21 0.64
(Mean surface areaSD cm2) 3.080.55 3.090.74 0.01 0.91 3.080.32 3.380.92 9.39 0.0026 3.110.47 3.180.16 0.17 0.68
(Mean thicknessSD cm) 0.550.04 0.550.05 0.006 0.94 0.530.01 0.530.08 0.05 0.82 0.510.01 0.520.02 0.10 0.76
Subcortical; nucleus accumbens
(mean volumeSD cm3)
1.240.20 1.340.27 8.82 0.0037 1.100.13 1.100.36 0.03 0.85 1.020.15 1.000.510 0.10 0.76
Significant findings in bold; Cortical thickness p< 0.0015, Subcortical p< 0.0071, surface and thickness: p< 0.025.
addition, schizophrenia patients with FRH, e.g., auditory halluci-
nations, consistently show functional abnormalities in speech and
language brain areas and dysfunction of verbal memory systems
during hallucinations (for an elaborate overview see (51). Also,
cognitive functioning has been found associatedwith the presence
and severity FRS. Patients, in particularly those with FRH, show
impairments in source monitoring or source attribution (52, 53).
Our findings need to be interpreted taking several limitations
into account. First, most of the patients in all three samples used
antipsychotic medication at time ofMRI scanning. Only informa-
tion on type of medication (typical/atypical/both) was available.
Therefore, we were not able to investigate the effect of life-time
dose on the association between FRS and brain volumes. Second,
in each of the three samples, patients with FRS were overrepre-
sented (64% in sample A, 86% in sample B and 94% in sample
C) leading to large differences in group size when performing
group comparison. However, this distribution is largely in line
with incidences reported in the literature (1–4).
Another limitation may be that FRS as a concept is broad
and possibly consist of symptoms with different underlying brain
pathology. Previously, we (and others) showed that FRS consist
of two interrelated clusters of positive symptoms that interfere
with boundaries of self and other (54–56), i.e., a cluster of audi-
tory hallucinations (FRH, i.e., audible thoughts, conversational
voices, and voices commenting on one’s actions) and a cluster
of passivity delusions (FRD, i.e., thought withdrawal, thought
broadcasting, thought insertion, and beliefs that impulses and/or
actions are controlled by an outside force). Imaging studies that
focused specifically on FRH demonstrated reduced gray matter
volumes in sensory regions (51), a thinner cortex in the pars
orbitalis, para-central lobule, fusiform gyrus, and inferior tempo-
ral gyrus (57) in patients with auditory hallucination as compared
to controls and non-schizophrenia hallucinators. Also abnormal
brain measures have been found in patients with FRD as com-
pared to those without, albeit in different areas, i.e., reduced
cortical volume in parietal and frontal areas (15), increased
fractional anisotropy in the frontal cortex, cingulate gyrus,
and basal ganglia, and decreased fractional anisotropy in the
thalamus (17).
In conclusion, first rank symptoms have since long lost their
diagnostic relevance for psychotic disorders in general and
schizophrenia in particular. Their presence is associated with a
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number of specific cognitive and functional brain abnormalities,
e.g., differences in language areas or deficits in sense of agency,
suggesting that specific neural abnormalities may underlie FRS.
However, we found only subtle volume decreases in the accum-
bens and pars-opercularis, which were inconsistent between three
independent samples.
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